Regulatory Requirements for the Drug Approval Process in USA

The regulatory requirements for the approval of new drugs vary across different countries, making it challenging to establish a single regulatory approach for marketing authorization applications (MAAs). Understanding the regulatory requirements for each country is crucial. The drug approval process involves the submission of a New Drug Application (NDA) to the respective regulatory authority for permission to market a new drug. The NDA includes preclinical and clinical test data, drug information, and manufacturing procedures.

Phases of Clinical Trials

1. Preclinical Study: Conducted on animals such as mice, rats, rabbits, and monkeys.
2. Phase I - Human Pharmacology Trial: Estimation of safety and tolerability in a small group of human subjects.
3. Phase II - Exploratory Trial: Estimation of effectiveness and short-term side effects in a larger group of subjects.
4. Phase III - Confirmatory Trial: Confirmation of therapeutic benefits by studying larger populations and assessing safety.
5. Phase IV - Post-Marketing Trial: Studies conducted after drug approval to explore new uses, long-term effects, and different dosages.

NDA Evaluation Process

Upon receipt of the NDA by the regulatory agency, a technical screening is conducted to ensure that sufficient data and information have been submitted in each area for "filing" the application. At the conclusion of the NDA review, the regulatory body can take three possible actions:

1. Not Approvable: A letter is sent to the sponsor listing deficiencies and explaining the reasons for non-approval.
2. Approvable: The drug can be approved, but minor deficiencies such as labeling changes may need to be addressed. The regulatory body may also request post-approval studies.
3. Approval: A letter is sent stating that the drug is approved for marketing.

If the action taken is either "approvable" or "not approvable," the regulatory body provides the applicant with an opportunity to meet and discuss the deficiencies.

Regulation of the drug approval process

Drug Approval Process in the United States

The United States has stringent standards for approving new drugs, with the Food and Drug Administration (FDA) responsible for protecting and promoting public health. The drug approval process in the U.S. consists of two phases: 

1. Clinical trials (CT) 
2. NDA approval.

Investigational New Drug (IND) Application

Before the FDA approval process begins, the sponsor submits an Investigational New Drug (IND) application after preclinical trials have demonstrated the drug's safety. The IND application should provide high-quality preclinical data to justify testing in humans. Approximately 85% of drugs undergo clinical trials, and it is the responsibility of the sponsor to submit the IND application.

ALSO READ: The Vital Role of Artificial Intelligence in the Pharmaceutical Industry

Pre-IND Meeting

A pre-IND meeting can be arranged with the FDA to discuss various issues, including the design of animal research, the clinical trial protocol, and the chemistry, manufacturing, and control of the investigational drug. This meeting helps the sponsor gather data, organize animal research, and design the clinical protocol based on FDA suggestions.

Clinical Trials Phases

1. Phase I: Conducted on a small group of human subjects (~100) to evaluate the drug's safety profile and pharmacokinetics.
2. Phase II: Performed if the drug successfully passes Phase I, involving a larger group of subjects (~300) to evaluate dosage, efficacy, and additional safety.
3. Phase III: Involves several hundred to around 3,000 people and focuses on safety and effectiveness, examining different populations, dosages, and drug combinations.

New Drug Application (NDA)

An NDA can only be filed if the drug successfully completes all three phases of clinical trials. The NDA includes preclinical and clinical reports, data analyses, drug pharmacokinetics, manufacturing details, and proposed labeling. A team of scientists at the Center for Drug Evaluation and Research reviews the reports, and risk-benefit analysis, and determines if the new drug is relatively safe, effective, and does not pose unreasonable risks.

NDA Approval

The approval of an NDA typically takes around two years, although the process duration can vary. Once approved, the innovating company can market the drug and enters Phase IV trials. In Phase IV, additional areas of the drug's application, new populations, long-term effects, and different dosages are explored.

The drug approval process in the USA

Conclusion

The drug approval process is a rigorous and multi-phased procedure that involves preclinical and clinical trials, IND application, and NDA submission. The United States has one of the most demanding drug approval standards globally, overseen by the FDA. Understanding the regulatory processes and requirements is crucial for pharmaceutical companies seeking to bring new drugs to the market successfully.

ALSO READ: Drug Regulatory Affairs